Our data demonstrate that tumor cells disrupt GC reactions via MIF-CXCR4 interactions, suggesting that GC evaluation, combined with MIF or HMGCR assessment, could refine biomarkers for immunotherapy sensitivity. Here, CXCR4 is linked to neoplasm.